Introduction
Obesity represents one of the most significant public health challenges of the 21st century, affecting over 650 million adults worldwide and contributing to approximately 2.8 million deaths annually[1]. This complex chronic condition, characterized by excessive fat accumulation that presents a risk to health, has nearly tripled in prevalence since 1975. Beyond its immediate health implications, obesity significantly increases the risk of numerous comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and psychological disorders, creating an enormous burden on healthcare systems globally.
The management of obesity has undergone a remarkable evolution over the past century. Early approaches were predominantly characterized by simplistic “eat less, move more” paradigms, often accompanied by stigmatizing attitudes that viewed obesity primarily as a failure of willpower or character. These simplistic approaches typically yielded disappointing long-term outcomes, with most individuals regaining lost weight within 3-5 years. This pattern of weight cycling, sometimes called “yo-yo dieting,” often left patients discouraged and sometimes in worse metabolic health than before intervention.
Contemporary understanding of obesity has shifted dramatically, with the condition now recognized as a complex, multifactorial chronic disease influenced by genetic, epigenetic, physiological, psychological, and environmental factors. This more nuanced understanding has driven the development of more sophisticated and multifaceted treatment approaches. Modern obesity management acknowledges that sustainable weight management typically requires addressing multiple aspects of this complex condition concurrently.
The spectrum of modern obesity interventions ranges from dietary modifications and structured physical activity programs to advanced behavioral therapies, pharmacological agents, and bariatric surgical procedures. Each approach offers distinct advantages and limitations, with effectiveness varying considerably between individuals. This heterogeneity in treatment response underscores the importance of personalized approaches to obesity management, tailored to individual physiology, psychology, preferences, and circumstances.
Perhaps the most significant recent development in the field has been the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for type 2 diabetes management but now recognized as powerful tools for weight management. These agents have demonstrated unprecedented efficacy in clinical trials, producing weight loss magnitudes previously achievable only through bariatric surgery.
This article examines the evolution and current landscape of obesity management approaches, from traditional dietary interventions to the latest GLP-1 receptor agonist therapies. We will explore the scientific evidence supporting various approaches, their limitations, and the growing consensus that effective obesity management requires a comprehensive approach integrating nutritional, pharmacological, behavioral, and sometimes surgical interventions. The ultimate goal of modern obesity management is not merely weight loss but improved overall health and quality of life through sustainable, evidence-based strategies.
The Evolution of Dietary Approaches to Weight Management
The history of dietary approaches to weight management reflects broader cultural, scientific, and medical attitudes toward obesity across different eras. Early 20th century weight loss programs focused primarily on caloric restriction, often with severely restrictive diets that were difficult to maintain and frequently nutritionally inadequate. The post-World War II period saw the emergence of commercial weight loss programs like Weight Watchers (founded in 1963), which introduced elements of behavioral support and group accountability to dietary interventions.
By the late 20th century, the dietary landscape had fragmented into competing paradigms, each claiming superior effectiveness for weight management. Low-fat approaches dominated nutritional recommendations through the 1980s and 1990s, based on the seemingly logical premise that reducing dietary fat would reduce body fat accumulation. This period saw an explosion of low-fat and “fat-free” commercial food products. However, population weight continued to rise, and subsequent research revealed that many low-fat processed foods contained high levels of refined carbohydrates and sugars, potentially contributing to rather than alleviating obesity trends[2].
The early 2000s witnessed a pendulum swing toward low-carbohydrate approaches, popularized by the Atkins diet and its derivatives. These diets, which drastically reduce carbohydrate intake while allowing relatively liberal consumption of proteins and fats, demonstrated impressive short-term weight loss results in numerous clinical trials. The proposed mechanisms include reduced insulin levels, leading to enhanced fat oxidation, alongside increased satiety from higher protein intake. Meta-analyses have shown that low-carbohydrate diets typically produce greater weight loss than low-fat approaches in trials lasting up to 12 months, though differences tend to diminish over longer periods.
Concurrently, interest grew in dietary patterns associated with positive health outcomes in observational studies. The Mediterranean diet, characterized by abundant plant foods, moderate fish consumption, limited red meat, and olive oil as the primary fat source, has demonstrated benefits for weight management alongside improvements in cardiovascular risk factors. Similarly, various forms of intermittent fasting have gained scientific and popular attention, with evidence suggesting that manipulating eating windows without necessarily reducing food types can produce meaningful metabolic benefits and moderate weight loss.
The 2010s saw increasing recognition that dietary adherence, rather than specific macronutrient composition, may be the most important determinant of weight loss success. This understanding has shifted focus toward personalized approaches that consider individual preferences, cultural background, and metabolic responses to different dietary patterns. Emerging technologies including continuous glucose monitoring have enabled researchers and clinicians to observe idiosyncratic responses to identical meals among different individuals, challenging one-size-fits-all dietary prescriptions.
Modern nutritional approaches increasingly acknowledge that sustained adherence to any dietary pattern requires addressing multiple factors beyond mere food composition. These include food environment, emotional relationships with eating, cultural contexts, cooking skills, and economic constraints. Consequently, effective dietary interventions now commonly integrate psychological support, culinary education, and practical strategies for navigating challenging food environments.
The limitations of diet-centered approaches have become increasingly apparent, with systematic reviews consistently showing modest long-term effectiveness when used in isolation. Most dietary interventions produce weight loss plateaus after 6-8 months, followed by partial weight regain even with continued adherence. This pattern reflects the body’s complex compensatory mechanisms that defend against sustained weight loss, including metabolic adaptation, changes in hunger and satiety hormones, and altered neural responses to food cues.
These limitations have driven the integration of nutritional approaches with other treatment modalities. Current best practices typically combine evidence-based dietary strategies with structured physical activity programs, behavioral interventions, and, when appropriate, pharmacological or surgical approaches. This evolution reflects growing recognition that obesity is a chronic condition requiring comprehensive, long-term management strategies rather than short-term dietary “fixes.”
Behavioral and Lifestyle Interventions Beyond Diet
While dietary modifications form a cornerstone of obesity management, substantial evidence indicates that broader behavioral and lifestyle interventions significantly enhance treatment outcomes. Physical activity represents a particularly critical component, with multiple mechanisms contributing to its beneficial effects. Beyond the direct caloric expenditure during exercise, regular physical activity improves insulin sensitivity, enhances fat oxidation, preserves lean muscle mass during weight loss, and positively impacts appetite regulation hormones. Importantly, consistent physical activity strongly predicts long-term weight maintenance after initial weight loss, a phase where many traditional interventions fail.
Current guidelines recommend 150-300 minutes of moderate-intensity aerobic activity weekly for general health, with higher volumes (300+ minutes weekly) often necessary for substantial weight loss or maintenance after weight reduction. Resistance training at least twice weekly complements aerobic activity by preserving or increasing metabolically active lean tissue. However, adherence to these recommendations remains challenging for many individuals, highlighting the need for structured behavioral support and strategies tailored to diverse preferences, capabilities, and circumstances.
Psychological approaches have evolved significantly in recent decades, with cognitive-behavioral therapy (CBT) emerging as the most empirically supported psychological treatment for obesity. Modern CBT for weight management addresses maladaptive eating behaviors, unhelpful thought patterns, emotional eating triggers, and skills deficits that maintain excess weight. Mindfulness-based interventions have also shown promise, helping individuals develop greater awareness of hunger and satiety cues, reduce automatic or stress-triggered eating, and improve self-regulation. These approaches recognize that sustainable weight management requires addressing the complex psychological factors that influence eating behavior beyond simple knowledge of nutritional principles.
The digital revolution has transformed behavioral interventions for obesity through smartphone applications, wearable devices, and online platforms. These technologies facilitate self-monitoring (a cornerstone of behavioral treatment), provide real-time feedback, deliver evidence-based content, and connect users with professional support and peer communities. A 2021 meta-analysis found that digital interventions produced significantly greater weight loss compared to minimal or no intervention, though typically less than intensive face-to-face programs[3]. The scalability and accessibility of digital approaches make them particularly valuable for reaching populations with limited access to traditional healthcare services.
Emerging evidence highlights the importance of factors beyond traditional diet and exercise paradigms. Sleep quality and duration significantly impact weight regulation through multiple pathways, including effects on hunger hormones, insulin sensitivity, and food reward processing. Chronic sleep deprivation (less than 7 hours nightly) associates with increased obesity risk and poor weight loss outcomes. Similarly, chronic stress increases cortisol levels, which promotes abdominal fat deposition and drives emotional eating behaviors. Consequently, comprehensive lifestyle interventions increasingly incorporate sleep hygiene practices and stress management techniques alongside traditional components.
Chronobiology—the science of biological rhythms—offers another promising avenue for intervention. Time-restricted eating (confining food consumption to specific daily windows) has shown beneficial effects on metabolic parameters and modest weight loss in numerous trials. These approaches align food intake with circadian rhythms that optimize metabolic function, potentially enhancing the effectiveness of caloric restriction while improving adherence through simple temporal rules rather than complex dietary prescriptions.
The most effective behavioral programs typically integrate multiple components into structured, high-intensity interventions. The Diabetes Prevention Program and Look AHEAD (Action for Health in Diabetes) trials demonstrated that comprehensive lifestyle interventions combining dietary modification, physical activity, regular self-monitoring, and ongoing behavioral support could achieve clinically significant weight loss (5-10% of initial weight) and maintain substantial portions of these losses over extended periods. However, these intensive programs require considerable resources and professional expertise, highlighting the implementation challenges for widespread dissemination.
Despite their demonstrated effectiveness, behavioral and lifestyle interventions face significant limitations when used in isolation, particularly for individuals with severe obesity or significant physiological dysregulation. Recognition of these limitations has driven increasing integration of behavioral approaches with appropriate pharmacological and surgical interventions in comprehensive, individualized treatment plans.
Pharmacological Approaches: The Pre-GLP-1 Era
The history of pharmacological interventions for obesity is characterized by cycles of initial enthusiasm followed by recognition of significant limitations, safety concerns, and, in several cases, market withdrawals. Early attempts at medication-assisted weight management in the mid-20th century primarily utilized amphetamine derivatives and related compounds that suppressed appetite through central nervous system stimulation. While effective for short-term weight reduction, these medications carried substantial risks of dependency, cardiovascular complications, and psychiatric side effects, leading to restricted usage and eventually discontinued marketing of many agents.
The modern era of obesity pharmacotherapy began in the 1990s with two distinct approaches: sibutramine (Meridia), a serotonin-norepinephrine reuptake inhibitor that enhanced satiety signaling, and orlistat (Xenical), a pancreatic lipase inhibitor that reduced dietary fat absorption in the intestine. Both medications demonstrated modest efficacy in clinical trials, typically producing additional weight loss of 3-5% beyond lifestyle intervention alone. However, sibutramine was withdrawn from global markets in 2010 due to increased cardiovascular event rates in high-risk patients, highlighting the safety challenges in developing obesity pharmacotherapy.
Orlistat remained available but achieved limited uptake due to unpleasant gastrointestinal side effects, including oily spotting, flatus with discharge, and fecal urgency. These effects, while not dangerous, significantly impacted quality of life and medication adherence. Moreover, orlistat’s mechanism necessitated following a low-fat diet to minimize side effects, creating a situation where the medication essentially enforced dietary compliance through negative reinforcement rather than addressing the underlying physiological drivers of weight gain.
The mid-2010s saw the approval of several new anti-obesity medications, including phentermine/topiramate extended-release (Qsymia), naltrexone/bupropion sustained-release (Contrave), and liraglutide 3.0 mg (Saxenda). These agents represented refinements to existing pharmacological approaches rather than novel mechanisms. Phentermine/topiramate combined a sympathomimetic appetite suppressant with an anticonvulsant that exhibits weight loss properties through unclear mechanisms. Naltrexone/bupropion paired an opioid antagonist with a norepinephrine-dopamine reuptake inhibitor to modulate reward pathways and reduce food cravings. Liraglutide, a GLP-1 receptor agonist originally approved for diabetes management, received indication for obesity treatment at a higher dose based on its effects on appetite and gastric emptying.
These medications demonstrated improved efficacy compared to earlier agents, with mean placebo-subtracted weight losses ranging from approximately 4% (naltrexone/bupropion) to 9% (phentermine/topiramate) in pivotal trials lasting 56-104 weeks[4]. However, significant limitations remained. Side effect profiles—including cardiovascular concerns with phentermine/topiramate, nausea with liraglutide, and psychiatric effects with naltrexone/bupropion—restricted their suitability for many patients. Additionally, cost and limited insurance coverage created substantial access barriers, with many patients unable to afford these medications for the long-term use necessary in chronic disease management.
The regulatory pathway for obesity medications presented particular challenges during this period. Regulatory agencies required demonstration of both significant weight loss and improvements in cardiometabolic parameters, alongside rigorous safety monitoring. These appropriately strict standards reflected historical safety issues with weight loss medications but created a challenging development environment that limited investment in novel agents. Consequently, the pre-GLP-1 obesity pharmacotherapy landscape remained characterized by modest efficacy, significant tolerability issues, and restricted access.
Several key lessons emerged from this era. First, short-term pharmacotherapy typically produces transient benefits, with weight regain occurring upon medication discontinuation. This observation reinforced the conceptualization of obesity as a chronic condition requiring ongoing management rather than a temporary problem amenable to short-term intervention. Second, medications addressing single pathways demonstrated limited efficacy, reflecting the redundant biological systems regulating energy balance. Finally, the discrepancy between clinical trial outcomes and real-world effectiveness highlighted the importance of integrating pharmacotherapy with comprehensive lifestyle interventions and ongoing support.
These insights helped shape the development and implementation strategies for subsequent generations of anti-obesity medications, particularly the advanced GLP-1 receptor agonists that would transform the treatment landscape in the 2020s. The transition from earlier agents to these newer medications represents not merely incremental improvement but a paradigm shift in the effectiveness, tolerability, and physiological relevance of obesity pharmacotherapy.
The GLP-1 Revolution in Obesity Management
Glucagon-like peptide-1 (GLP-1) receptor agonists have fundamentally transformed the obesity treatment landscape, offering unprecedented efficacy with favorable safety profiles. Understanding this revolution requires examining both the underlying biology and the clinical development pathway that established these agents as cornerstone treatments for obesity.
GLP-1 is an incretin hormone naturally secreted by intestinal L-cells in response to nutrient intake. This 30-amino acid peptide exerts multiple effects relevant to weight regulation and metabolism. In the pancreas, GLP-1 enhances glucose-dependent insulin secretion while suppressing glucagon release, improving glycemic control without hypoglycemia risk. In the central nervous system, particularly the hypothalamus and brainstem, GLP-1 reduces appetite and food intake by modulating neural circuits controlling hunger and satiety. Additionally, GLP-1 slows gastric emptying, prolonging the sensation of fullness after meals, and may influence food reward processing in mesolimbic pathways. This multifaceted action addresses several pathophysiological mechanisms underlying obesity rather than targeting isolated pathways.
The development of GLP-1-based therapies began in the diabetes field, where the first-generation agent exenatide (Byetta) received FDA approval in 2005. Subsequent diabetes-focused GLP-1 receptor agonists included liraglutide (Victoza), dulaglutide (Trulicity), and semaglutide (Ozempic), each demonstrating progressive improvements in pharmacokinetic profiles, dosing convenience, and glycemic efficacy. Weight reduction consistently appeared as a “secondary benefit” in diabetes trials, prompting investigation of these agents specifically for obesity management.
Liraglutide 3.0 mg (Saxenda) became the first GLP-1 receptor agonist approved specifically for chronic weight management in 2014, based on the SCALE clinical program demonstrating approximately 5-6% greater weight loss than placebo over 56 weeks. While representing an advance over previous options, daily injection requirements and moderate efficacy limited its transformative impact. The true revolution began with semaglutide 2.4 mg (Wegovy), approved in 2021 following the STEP clinical trial program that demonstrated unprecedented efficacy for a non-surgical intervention.
In the pivotal STEP-1 trial, participants receiving weekly semaglutide injections lost an average of 14.9% of baseline body weight after 68 weeks, compared with 2.4% in the placebo group. Remarkably, 86% of semaglutide recipients achieved ≥5% weight loss (versus 32% with placebo), and 50.5% achieved ≥15% weight loss (versus 4.9% with placebo)[5]. These results approached the effectiveness of bariatric surgery, traditionally considered the most effective obesity intervention, while offering a significantly less invasive approach. Subsequent trials demonstrated similar benefits across various populations, including those with diabetes, cardiovascular disease, and prior failed weight loss attempts.
Beyond simple weight reduction, semaglutide produced clinically meaningful improvements in cardiometabolic risk factors, including blood pressure, lipid profiles, glycemic parameters, and inflammatory markers. Patients also reported significant improvements in physical functioning and quality of life measures. These comprehensive benefits reflect the multiple mechanisms through which GLP-1 receptor agonists influence metabolism and weight regulation.
The safety profile of advanced GLP-1 receptor agonists represents another advance over previous pharmacotherapy options. The most common adverse effects are gastrointestinal—including nausea, vomiting, and diarrhea—which typically diminish with continued treatment and proper dose titration. Serious adverse events are rare, though monitoring is recommended for potential concerns including pancreatitis, gallbladder disease, and renal impairment in susceptible individuals. Importantly, large cardiovascular outcomes trials in diabetes populations have demonstrated cardiovascular safety and even protective effects with certain GLP-1 receptor agonists, contrasting sharply with the cardiovascular concerns that led to withdrawal of previous weight management medications.
Patient selection for GLP-1 therapy requires careful consideration of several factors. Current guidelines recommend these agents for individuals with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, as an adjunct to lifestyle interventions. Contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, and history of pancreatitis. Beyond these formal criteria, clinicians typically consider comorbidity profiles, previous treatment responses, medication access, and patient preferences when recommending GLP-1 therapy.
Despite their remarkable effectiveness, significant challenges limit the real-world impact of GLP-1 receptor agonists. Cost represents the most substantial barrier, with monthly expenses exceeding $1,000 for some formulations in the absence of insurance coverage. Even with insurance, variable coverage policies and high copayments create financial obstacles for many patients. Manufacturing capacity constraints have further complicated access, with periodic shortages affecting medication availability. These limitations have raised important questions about equity in obesity treatment, as those most affected by obesity often have the least access to these transformative medications.
The treatment landscape continues to evolve rapidly, with newer agents including tirzepatide (a dual GIP/GLP-1 receptor agonist) demonstrating even greater efficacy in clinical trials. The development of oral formulations with improved bioavailability may eventually reduce the need for injections, potentially expanding acceptability and access. Meanwhile, research into combination approaches and optimal duration of therapy continues to refine the clinical implementation of these powerful interventions.
Integrated Approaches: The Future of Obesity Management
The evolution of obesity treatment has clearly demonstrated that single-modality approaches rarely achieve optimal long-term outcomes. Contemporary obesity management increasingly embraces multimodal strategies that address the complex, multifaceted nature of this chronic condition. This integrated approach recognizes obesity as a heterogeneous disorder with varied etiologies, presentations, and optimal intervention points across individuals.
The complementary mechanisms of dietary, behavioral, and pharmacological interventions provide strong rationale for their combination. GLP-1 receptor agonists modify appetite signals and food preferences at a neurobiological level, creating a physiological environment more conducive to dietary adherence. Concurrently, evidence-based dietary approaches provide the nutritional framework to optimize both weight loss and broader health outcomes. Behavioral interventions address psychological factors that influence eating behavior while developing sustainable habits that support long-term weight management. This synergistic relationship potentially overcomes the limitations of each approach used in isolation.
Emerging evidence supports the enhanced effectiveness of combined interventions. Studies examining GLP-1 therapy alongside structured lifestyle interventions have demonstrated greater weight loss and improved cardiometabolic parameters compared to either approach alone. Importantly, behavioral support appears to enhance medication adherence and management of side effects, while pharmacotherapy reduces the biological drive to overeat that often undermines behavioral approaches. This bidirectional relationship creates a positive cycle that improves outcomes across multiple domains.
Digital health technologies increasingly facilitate the implementation of comprehensive treatment programs. Smartphone applications can simultaneously support dietary monitoring, physical activity tracking, medication management, and behavioral skill development, while connecting patients with healthcare providers for remote monitoring and timely adjustments. Artificial intelligence and machine learning algorithms offer the potential for increasingly personalized recommendations based on individual response patterns and preferences. These digital tools may help bridge the gap between intensive clinical programs and scalable real-world implementations.
The pharmacological landscape continues to evolve rapidly, with combination therapies representing a particularly promising direction. Agents targeting multiple hormonal pathways—such as GLP-1/GIP dual agonists and GLP-1/glucagon co-agonists—have demonstrated enhanced efficacy in clinical trials. Other investigational approaches include combination of incretin-based therapies with agents addressing complementary mechanisms, such as amylin analogues and leptin sensitizers. These combinations aim to address multiple pathophysiological aspects of obesity concurrently, potentially overcoming the compensatory mechanisms that often limit single-agent approaches.
Comprehensive obesity management requires addressing factors beyond the individual level. Socioeconomic determinants—including food insecurity, neighborhood resources, educational opportunities, and healthcare access—profoundly influence obesity risk and treatment outcomes. Environmental factors such as food marketing, portion sizes, urban design, and transportation systems create contexts that either support or undermine individual weight management efforts. Truly integrated approaches acknowledge these broader influences and incorporate appropriate advocacy, policy initiatives, and community-level interventions alongside individual treatment plans.
Implementing comprehensive obesity care faces several practical challenges. The fragmented healthcare system often separates nutritional, psychological, and medical aspects of treatment across different providers and reimbursement systems. Time constraints in typical clinical encounters limit providers’ ability to address the multiple components of effective obesity management. Additionally, many healthcare professionals receive limited training in obesity’s complex etiology and evidence-based management approaches, leading to oversimplified and potentially stigmatizing care.
The promise of truly personalized obesity management appears increasingly achievable through advances in multiple domains. Genetic and metabolomic profiling may eventually predict individual responses to specific dietary patterns, exercise regimens, and pharmacological agents. Digital phenotyping through wearable devices and smartphone interactions can provide real-time data on behavioral patterns and environmental influences. Integration of these diverse data streams could theoretically produce highly individualized treatment plans tailored to each person’s unique biology, psychology, and circumstances.
The future of obesity management lies in these integrated, personalized approaches that acknowledge obesity’s chronicity and complexity while respecting individual preferences and circumstances. Moving beyond simplistic paradigms that have dominated past approaches, modern obesity care embraces the complementary roles of nutritional science, behavioral psychology, pharmacology, technology, and environmental modification in addressing one of the most significant public health challenges of our time.
Conclusion
The management of obesity has undergone a remarkable transformation over recent decades, evolving from simplistic, often ineffective approaches to sophisticated, multifaceted strategies informed by advances in our understanding of this complex condition. This evolution reflects the recognition of obesity as a chronic disease with multiple biological, psychological, and environmental determinants rather than simply a matter of personal choice or willpower.
The dietary approaches that once dominated obesity treatment remain important components of comprehensive management but are now understood within a broader context. Modern nutritional strategies acknowledge the importance of sustainability, personal preference, and metabolic individuality rather than promoting rigid, one-size-fits-all prescriptions. Similarly, behavioral interventions have progressed from basic advice to structured programs addressing the complex psychological factors that influence eating behavior and physical activity patterns.
Perhaps the most dramatic advancement has occurred in the pharmacological domain, particularly with the development of GLP-1 receptor agonists that offer unprecedented efficacy with favorable safety profiles. These medications, by addressing fundamental biological drivers of weight regulation, create opportunities for successful management in patients who have struggled with traditional approaches. However, their optimal implementation occurs within comprehensive programs that include appropriate nutritional, behavioral, and environmental components.
Despite these significant advances, substantial challenges remain in obesity management. Access inequities represent a particular concern, with effective treatments often least available to those most affected by obesity and its complications. The high cost of newer pharmaceutical agents, limited insurance coverage, and shortages of healthcare professionals trained in comprehensive obesity management all contribute to a treatment landscape characterized by significant disparities. Addressing these systemic issues requires policy changes, healthcare restructuring, and ongoing efforts to reduce obesity stigma within medical and broader societal contexts.
Looking forward, several promising developments may further transform obesity management. Advanced pharmacological combinations targeting multiple pathways offer the potential for even greater efficacy. Digital health technologies increasingly facilitate personalized, accessible care delivery outside traditional clinical settings. Emerging research in precision nutrition and exercise prescription may eventually allow truly individualized treatment plans based on genetic, metabolic, and behavioral profiles.
The evolution from simplistic diets to sophisticated, integrated approaches represents remarkable progress in addressing one of our most significant public health challenges. However, the full potential of modern obesity management can only be realized through commitment to evidence-based, patient-centered care that acknowledges the complex, chronic nature of obesity while remaining accessible to the diverse population affected by this condition. The future of obesity management lies not in seeking single “breakthrough” treatments but in thoughtfully integrating our expanding arsenal of evidence-based approaches to meet the unique needs of each individual.
References
- World Health Organization. (2023). [Obesity and overweight]
- Ludwig DS, et al. (2018). [Dietary fat: From foe to friend?]
- Fakih El Khoury C, et al. (2021). [Effectiveness of digital interventions for weight management in school-aged children and adolescents: A systematic review and meta-analysis]
- Khera R, et al. (2016). [Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis]
- Wilding JPH, et al. (2021). [Once-Weekly Semaglutide in Adults with Overweight or Obesity]
